Liver morbidity · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Quality of life SF 36 and CLDQ · people with chronic hepatitis C
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).
1 finding from 1 review
Progression to fulminant HBV infection · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with acute HBV infection
1 finding from 1 review
Adverse events (proportion) (4 to 6 months) · people with acute HBV infection
Interferon may leads to higher adverse events (proportion) (4 to 6 months) compared with no intervention (low certainty).
1 finding from 1 review
Adverse events (number of events) · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (1 week) · people with acute HBV infection
It is very uncertain whether interferon changes health‐related quality of life (1 week) compared with no intervention (very low certainty).
1 finding from 1 review
Short‐term mortality · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to chronic HBV infection · people with acute HBV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of herpes labialis during use of the preventative intervention ‐ presurgical · participants with recurrent herpes labialis
Interferon may leads to higher incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention ‐ postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention ‐ pre‐ and postsurgical · participants with recurrent herpes labialis
Interferon may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ presurgical · participants with recurrent herpes labialis
Interferon probably leads to higher adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ pre‐ and postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality or liver‐related morbidity · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
OR 1.14 [0.38, 3.42]
1789 participants
Low